Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0917801 (insomnia)
 10,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The study on the effect of the "tiapride" on the elements due to the withdrawal syndrome effected on thirty alcoholic patients allows us to draw the following results: failure, 13% studied cases; partial results, 50% very good results, 37%. The effect on the shivering was considered as good, but the effect on insomnia and anxiety was moderate. It appears that the doses which have been used are unsufficient to use this medecine as a "monotherapy". The authors intend to carry on this study using more important doses, taking into account the excellent tolerance observed.
Sem Hop
PMID:[The prevention of alcohol withdrawal syndrome (author's transl)]. 3 43

Thirthy-three alcoholics, aged between 31 and 82 years, were treated for 7 to 30 days with tiapride. The dosage was 600 mg/day (200 mg 3 times daily) by mouth or 100 to 800 mg/day I.M. Out of 27 cases of tremor treated, there were 25 favourable results, one average result and one nil result. Insomnia and character disorders, e.g. anguish, depression, nightmares, hallucinations, were improved during the first few days of treatment in 27 cases out of 30. Out of 12 cases of algo-paresthesia of the lower limb treated, the were 9 good or excellent results, 2 average results and 1 nil result. A favourable result was observed in 7 cases out of nine in vomiting, water brash (3 cases out of 4), and in 16 cases out of 20 in anorexia. No clinical or laboratory disturbance attributable to tiapride was noted in our patients whose general health was often very poor.
Sem Hop 1978 Mar
PMID:[Tiapride and alcoholic disorders of central origin. Apropos of 33 cases]. 21 35

The responsibility of the folate deficiency in some neuropsychiatric disorders is recent knowledge. The role of the folate on the nervous system is not yet well definite, but the action on the metabolism of the amino-acids, on the purine and the pyrimidine synthesis and on the metabolism of the catecholamins are certainly essential. The neuropsychiatric diseases secondary to the folate deficiency are numerous: dementia, schizophrenia like syndromes, insomnia, irritability, forgetfulness, endogenous depression, organic psychosis, pueperal psychosis, peripheral neuropathy, myelopathy (spinal cord syndrome and/or pyramidal tract damage), restless legs syndrome. Clinically the diagnosis may be difficult with sub acute combined degenration secondary to the pernicious anaemia, and the dosage of the folate (in serum, in red-cells and in cerebrospinal fluid) is necessary. The congenital defects in the uptake or utilization of the folate are associated with neuropsychiatric disturbances. The treatment is easy and safe if the vitamin B12 deficiency is eliminated and if employed with caution in epileptic patients because folate can induced seizures.
Sem Hop
PMID:[Folate and the nervous system (author's transl)]. 22 16

The efficiency of flunitrazepam was evaluated on the three phases of sleep in 20 patients 65 years old and more hospitalized suffering from severe insomnia. The experiment lasted 6 days. The initial dosage of half a tablet was sufficient and was maintained in 13 patients. In 5 subjects, dosage had to be increased to one tablet. In one subject, it was reduced to a quarter of a tablet. In the three quarters of the patients, the onset of sleep was of better quality; their actual sleep was longer and also of higher quality. The waking up was much easier in 18 patients who felt relaxed and alert during the morning. The alertness tests confirmed the patients state. The efficiency was satisfactory and the tolerance was very good. Taking into account the individual sensitivity of the aged, initial dosages must be small and adjusted according to the therapeutic responses.
Sem Hop
PMID:[Study of flunitrazepam in the insomnia of the aged (author's transl)]. 610 78

A group of 78 women with sudden flushes and associated disorders (pruritus vulvae, headache, anxiety, instability, depression, libido disturbances) related to the menopause were treated with one or two capsules of veralipride daily for 20 days. Excellent or good results were obtained in 54 of the 69 patients (78 p. cent) with sudden flushes, and 29 of the 57 cases (51 p. cent) with associated disorders. The difference in scores before and after treatment is very highly significant (p < 0.001). Clinical tolerance was good as only 2 cases of minimal galactorrhea. 2 cases of mastodynia, 3 cases with mild drowsiness, 2 patients with nervous tension or insomnia, 3 with digestive disorders, 1 with vertigo, and 1 with mild visual disturbances were observed. No modifications in the biological parameters studied were noted. Blood prolactin levels increased during treatment but returned to normal levels 4 days after discontinuation of therapy. No significant modifications in FSH, LH, E2, or E3 plasma levels were noted at the end of the study. Veralipride appears, therefore, to be the prototype for non-hormonal therapy of menopausal disorders.
Sem Hop 1980 Oct 15
PMID:[A new therapeutic approach to menopausal sudden flushes and psychofunctional disorders (author's transl)]. 625 60

Common obstacles to rehabilitation of patients having suffered severe trauma are lability of attention and relational difficulties with the physician. Major psychopharmaceutic agents often hinder adequate motor function. Tiapride was used in twelve patients with psychological and/or motor difficulties slowing rehabilitation. The average daily dosage was 600 mg orally (divided in three doses of two tablets each), during seven weeks. In three patients, the difficulties disappeared completely. The major problems disappeared in six patients and were improved in one. The treatment failed in two cases. Tolerance was excellent in spite of the poor condition of many of the patients. The only side-effects were marked drowsiness in one patient and negligible drowsiness or insomnia in four.
Sem Hop
PMID:[Tiapride and rehabilitation (author's transl)]. 627 Aug 17

Tiapride was used in 55 chronic alcoholics. It has a sedative effect on the anxiety, aggressiveness and agitation observed during the alcohol withdrawal syndrome. It is also effective against tremor, insomnia and fatigue. Fatigue or depression do not occur as side-effects. Tiapride induces a psychological feeling of wellbeing which is heightened by continuation of detoxication and general management.
Sem Hop
PMID:[Tiapride in detoxication of chronic alcoholics (author's transl)]. 627 32

The effectiveness of tiapride on psychic disorders was studied in 30 chronic alcoholics by assessing four parameters: sleep disturbances, mood disorders, conduct disturbances, and tremor. In a daily dosage of 600 to 900 mg tiapride proved particularly effective on insomnia, anxiety, passivity and tremor, without adverse side-effects. This drug seems useful for controlling psychic disorders in alcoholics and for motivating acceptance of a detoxification program.
Sem Hop 1982 Sep 23
PMID:[Study of the effectiveness of tiapride on psychic disorders in alcoholics]. 629 77

The aim of this study is to evaluate the efficiency of a treatment prescribed, in the course of an hospital consultation for sleep pathology, to patients suffering from chronic insomnia not improved by longstanding and sustained medication with hypnotic drugs. The basis of the treatment is a progressive but total withdrawal of hypnotics in so far taken regularly. The withdrawal of hypnotics was prescribed to 79 patients: 33 aged 17 to 39 years (group 1, mean age 30) and 46 aged 40 to 70 years (group 2, mean age 51). 41 showed primary psychophysiological insomnia and 28 showed insomnia associated with psychiatric disorders. In patients of group 1, the average durations were 8 years for insomnia and 3 years for sustained hypnotic use; these durations were 15 and 5 years respectively in patients of group 2. Hypnotic drug withdrawal was achieved without placebos in 3 months in group 1 patients and 5 months in group 2 patients. 65 patients completely stopped the continual use of hypnotics. Subjective improvement of insomnia was reported by 51 of these patients (as well as by 6 patients who were given simultaneous antidepressant therapy). 16 of the 51 improved patients have resorted to hypnotics occasionally (at intervals of 10 days or more). After complete withdrawal, patients went on consulting for various lengths of time: 5 months average for group 1, 14 months average for group 2. This study of a fairly large group of insomniacs shows the frequent ineffectiveness of a sustained use of currently available hypnotics. It also shows that two times out of three the complete stop of sustained hypnotic medication proved beneficial to the patient.
Sem Hop 1982 Nov 18
PMID:[Insomnia therapy and withdrawal of hypnotics]. 629 32

We studied the effect of tiapride on alcoholic and drug-dependent inpatients. In both the treatment was initiated at a time of acute intoxication. Tiapride was perfectly tolerated and we recorded none of the side effects seen with neuroleptics. The method of administration (continuous intravenous infusion) together with the mild sedative effect prompted the regressive response which is a necessary step before the subsequent reconstructive phase. The unquestionable though not overpowering sedative effect gives the patient a feeling of comfort and allows him to participate actively in the treatment. The second original characteristic of tiapride is that it's anxiolytic effect is mild, with the drawback of leaving anxiety and insomnia unalleviated. But this treatment has a novel advantage in that it does not induce any drug dependency, even secondarily.
Sem Hop 1982 Nov 18
PMID:[Tiapride in acute stages of drug addiction]. 629 40


1